VivoSim Labs VIVS
NASDAQ VIVS
$0.29 +0.01 (+3.06%)
At close: Aug 21, 2026 · 4:00 PM EDT

VivoSim Labs (VIVS) Revenue (2011 - 2026)

VivoSim Labs (VIVS) posted quarterly Revenue of $40000.0 for Q1 2026, down 21.57% year-over-year from $51000.0 in Q1 2025, and up 53.85% quarter-over-quarter from $26000.0 in Q4 2025.

VivoSim Labs (VIVS) Revenue (2011 - 2026) Analysis & Trends

VivoSim Labs' Revenue history runs 14 years deep, the most recent figure standing at $40000.0 for Q1 2026.

  • In Q1 2026, Revenue fell 21.57% year-over-year to $40000.0; the TTM figure through Mar 2026 stood at $131000.0 (down 9.03% YoY), while the FY2026 annual figure was $131000.0, down 9.03% from the prior year.
  • Revenue for Q1 2026 stood at $40000.0, up from $26000.0 in the prior quarter.
  • The five-year high for Revenue was $1.5 million in Q1 2022, with the low at $5000.0 in Q4 2023.
  • The 5-year median for Revenue is $39000.0 (2024), against an average of $150266.7.
  • The sharpest annual moves came in 2023 and 2024: Revenue tumbled 96.18% in 2023, then surged 380.0% in 2024.
  • VivoSim Labs' Revenue stood at $131000.0 in 2022, then sank by 96.18% to $5000.0 in 2023, then soared by 380.0% to $24000.0 in 2024, then climbed by 8.33% to $26000.0 in 2025, then soared by 53.85% to $40000.0 in 2026.
  • Business Quant data shows VIVS's Revenue at $40000.0 in Q1 2026, $26000.0 in Q4 2025, and $28000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 3.33 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 4.29 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 1.52 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 145.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 1.71 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 1.29 Bn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 1.06 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 425.49 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 674.14 Mn
10 VivoSim Labs 1.49 Mn 1.49 Mn - 18,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 18,000.00
Mar 31, 2026 40,000.00
Dec 31, 2025 26,000.00
Sep 30, 2025 28,000.00
Jun 30, 2025 37,000.00
Mar 31, 2025 51,000.00
Dec 31, 2024 24,000.00
Sep 30, 2024 30,000.00
Jun 30, 2024 39,000.00
Mar 31, 2024 29,000.00
Dec 31, 2023 5,000.00
Jun 30, 2023 75,000.00
Mar 31, 2023 162,000.00
Dec 31, 2022 131,000.00
Sep 30, 2022 77,000.00
Mar 31, 2022 1.50 Mn
Dec 31, 2019 298,000.00
Sep 30, 2019 1.23 Mn
Jun 30, 2019 668,000.00
Mar 31, 2019 680,000.00